The New Paper

November 23, 2020

AstraZeneca announces interim results from coronavirus vaccine trials

AstraZeneca announced that its coronavirus vaccine candidate is up to 90% effective based on interim results from late-stage clinical trials. Vaccine efficacy in the trial ranged from 62% to 90% (depending on the dosing regimen), and the company reported no serious safety events during the trials. The news follows announcements from Pfizer and Moderna last week, both of which found their vaccines to be ~95% effective in late-stage trials. 

Extra: Here’s a tracker of vaccines and treatments currently in development.

This story is from the November 23, 2020 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.